The increasing indications of FDG-PET/CT in Bladder Cancer

Nicolas Omorphos, Aruni Ghose, John Hayes, Abhinav Kandala, Prokar Dasgupta, Anand Sharma, Nikhil Vasdev

Research output: Contribution to journalArticlepeer-review


The management of locally advanced Muscle Invasive Bladder Cancer (MIBC) often necessitates neo-adjuvant chemotherapy (NAC) to
downstage the disease prior to definitive radical cystectomy (RC) and pelvic lymph node dissection (PLND). Assessing tumour response to NAC is crucial prior to planning definitive surgical treatment.
Review the evolving indications of functional F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in MIBC.
FDG-PET/CT is being increasingly utilised in local nodal staging and detection of metastatic disease in MIBC. Furthermore, it appears more accurate than conventional imaging modalities (CT/MRI) in assessing tumour response to NAC. This enables the earlier detection of tumour response and/or residual disease, impacting factors such as the duration of chemotherapy, with its associated adverse effects, and the timing of surgical intervention.
Patient Summary
Advanced bladder cancer that has invaded the muscle requires a combination treatment that may include chemotherapy prior to surgical removal of the bladder. The use of new imaging techniques, such as FDG-PET/CT, enables more accurate initial staging of bladder cancer (involvement of local lymph nodes or distant organs). In addition, it appears to be better at assessing cancer response to chemotherapy,
compared to the more traditional CT and MRI imaging.
Original languageEnglish
JournalEuropean Urology
Publication statusSubmitted - 4 Oct 2021


Dive into the research topics of 'The increasing indications of FDG-PET/CT in Bladder Cancer'. Together they form a unique fingerprint.

Cite this